Forward in reverse: how reverse genetics complements chemical genetics.
Pharmaceutical discovery has a renewed interest in physiological screening, while chemical genomics initiatives will soon provide a large amount of cellular assay data. However, there is no single robust approach to connect active compounds with their targets, limiting their experimental and therapeutic use. Systematic matching of chemical genetic phenotypes with reverse genetic phenotypes would provide a valuable starting point for many investigations.
Ross-Macdonald
Petra
P
Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 5400, Princeton, NJ 08543, USA. rossmacp@bms.com
D000818:Animals; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D005823:Genetics / Q000639:trends*; D006801:Humans; D010597:Pharmacogenetics / Q000639:trends*